{"id":17621,"date":"2022-07-25T15:48:27","date_gmt":"2022-07-25T14:48:27","guid":{"rendered":"https:\/\/psychedelichealth.co.uk\/?p=17621"},"modified":"2022-07-25T15:48:27","modified_gmt":"2022-07-25T14:48:27","slug":"psilocybin-alcohol-use-disorder-programme","status":"publish","type":"post","link":"https:\/\/psychedelichealth.co.uk\/2022\/07\/25\/psilocybin-alcohol-use-disorder-programme\/","title":{"rendered":"IND application submitted for psilocybin alcohol use disorder programme"},"content":{"rendered":"<h3 class=\"p1\"><b>B.More has submitted an Investigational New Drug (IND) application for its Psilocybin Alcohol Use Disorder Programme.<\/b><\/h3>\n<p class=\"p1\">According to the US Centers for Disease Control and Prevention, excessive alcohol use kills roughly 95,000 Americans each year and is the leading cause of preventable death.\u00a0<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p class=\"p1\">In addition to increased risk of chronic disease and death, excessive alcohol use can negatively impact memory, learning and mental health and carries massive economic and social costs.<\/p>\n<div style=\"clear:both; margin-top:0em; margin-bottom:1em;\"><a href=\"https:\/\/psychedelichealth.co.uk\/2022\/01\/11\/ketamine-assisted-therapy-alcohol-addiction\/\" target=\"_blank\" rel=\"dofollow\" class=\"u328b21ee4697c74c82088b355283d33d\"><style> .u328b21ee4697c74c82088b355283d33d { padding:0px; margin: 0; padding-top:1em!important; padding-bottom:1em!important; width:100%; display: block; font-weight:bold; background-color:#eaeaea; border:0!important; border-left:4px solid #34495E!important; text-decoration:none; } .u328b21ee4697c74c82088b355283d33d:active, .u328b21ee4697c74c82088b355283d33d:hover { opacity: 1; transition: opacity 250ms; webkit-transition: opacity 250ms; text-decoration:none; } .u328b21ee4697c74c82088b355283d33d { transition: background-color 250ms; webkit-transition: background-color 250ms; opacity: 1; transition: opacity 250ms; webkit-transition: opacity 250ms; } .u328b21ee4697c74c82088b355283d33d .ctaText { font-weight:bold; color:inherit; text-decoration:none; font-size: 16px; } .u328b21ee4697c74c82088b355283d33d .postTitle { color:#000000; text-decoration: underline!important; font-size: 16px; } .u328b21ee4697c74c82088b355283d33d:hover .postTitle { text-decoration: underline!important; } <\/style><div style=\"padding-left:1em; padding-right:1em;\"><span class=\"ctaText\">See also<\/span>&nbsp; <span class=\"postTitle\">Ketamine-assisted therapy for alcohol addiction could save lives<\/span><\/div><\/a><\/div>\n<p class=\"p1\"><a href=\"https:\/\/bmoreinc.org\/\" target=\"_blank\" rel=\"noopener\">B.More<\/a> is a non-profit, clinical-stage biopharmaceutical company focused on the development of psychedelic medicines for substance abuse disorders. Founded in 2017 by\u00a0Carey and Claudia Turnbull, B.More is named after Claudia Turnbull&#8217;s brother, Brett Moore, who died of a drug overdose 50 years ago<\/p>\n<p class=\"p1\">The company has submitted the application to begin a Phase\u00a02b\u00a0trial to determine the efficacy and safety of synthetic psilocybin (SYNP-101) in treating alcohol use disorder (AUD).\u00a0<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p class=\"p1\">The trial, which will be initiated in early 2023, will be led by principal investigator\u00a0Michael Bogenschutz, Director of the NYU Langone Center for Psychedelic Medicine.<\/p>\n<p class=\"p1\">Co-founder and CEO of B.More, Carey Turnbull, commented: \u201cB.More&#8217;s psilocybin AUD program IND application is a major step forward in our mission to develop psychedelic medicines for individuals struggling with alcohol use disorder. <span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p class=\"p1\">&#8220;Our Phase\u00a02b\u00a0trial builds on the impressive work led by Dr Bogenschutz and will provide vital data to further advance our drug development programme.\u201d<\/p>\n<p class=\"p1\">B.More&#8217;s Phase 2b, multicentre, randomised, double-blind, active placebo-controlled clinical trial will assess the 24-week efficacy and safety of synthetic psilocybin (SYNP-101) in treating moderate to severe alcohol use disorder (AUD). <span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p class=\"p1\">With a planned 226 participants, it will be the second largest psychedelics clinical trial ever conducted.<\/p>\n<p>[activecampaign form=52]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>B.More has submitted the application.<\/p>\n","protected":false},"author":20,"featured_media":17622,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_cbd_carousel_blocks":"[]","content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[235],"tags":[117,48,223],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v18.1 (Yoast SEO v22.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>IND application submitted for psilocybin alcohol use disorder programme<\/title>\n<meta name=\"description\" content=\"B.More has submitted an Investigational New Drug (IND) application for its Psilocybin Alcohol Use Disorder Programme.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/34.142.66.208\/2022\/07\/25\/psilocybin-alcohol-use-disorder-programme\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IND application submitted for psilocybin alcohol use disorder programme\" \/>\n<meta property=\"og:description\" content=\"B.More has submitted an Investigational New Drug (IND) application for its Psilocybin Alcohol Use Disorder Programme.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/34.142.66.208\/2022\/07\/25\/psilocybin-alcohol-use-disorder-programme\/\" \/>\n<meta property=\"og:site_name\" content=\"Psychedelic Health\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/Cannabis-Health-Magazine-1047415772315886\/?ref=bookmarks\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-25T14:48:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/34.142.66.208\/wp-content\/uploads\/2022\/07\/AdobeStock_223197658.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Stephanie Price\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@https:\/\/twitter.com\/steph_jprice\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Stephanie Price\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/34.142.66.208\/2022\/07\/25\/psilocybin-alcohol-use-disorder-programme\/\",\"url\":\"https:\/\/34.142.66.208\/2022\/07\/25\/psilocybin-alcohol-use-disorder-programme\/\",\"name\":\"IND application submitted for psilocybin alcohol use disorder programme\",\"isPartOf\":{\"@id\":\"https:\/\/34.142.66.208\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/34.142.66.208\/2022\/07\/25\/psilocybin-alcohol-use-disorder-programme\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/34.142.66.208\/2022\/07\/25\/psilocybin-alcohol-use-disorder-programme\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/psychedelichealth.co.uk\/wp-content\/uploads\/2022\/07\/AdobeStock_223197658.jpeg\",\"datePublished\":\"2022-07-25T14:48:27+00:00\",\"dateModified\":\"2022-07-25T14:48:27+00:00\",\"author\":{\"@id\":\"https:\/\/34.142.66.208\/#\/schema\/person\/188c12739a5906cf0b69fbf53f517f12\"},\"description\":\"B.More has submitted an Investigational New Drug (IND) application for its Psilocybin Alcohol Use Disorder Programme.\",\"breadcrumb\":{\"@id\":\"https:\/\/34.142.66.208\/2022\/07\/25\/psilocybin-alcohol-use-disorder-programme\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/34.142.66.208\/2022\/07\/25\/psilocybin-alcohol-use-disorder-programme\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/34.142.66.208\/2022\/07\/25\/psilocybin-alcohol-use-disorder-programme\/#primaryimage\",\"url\":\"https:\/\/psychedelichealth.co.uk\/wp-content\/uploads\/2022\/07\/AdobeStock_223197658.jpeg\",\"contentUrl\":\"https:\/\/psychedelichealth.co.uk\/wp-content\/uploads\/2022\/07\/AdobeStock_223197658.jpeg\",\"width\":1200,\"height\":800,\"caption\":\"UK-funded trial to investigate ketamine for alcohol addiction\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/34.142.66.208\/2022\/07\/25\/psilocybin-alcohol-use-disorder-programme\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/34.142.66.208\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IND application submitted for psilocybin alcohol use disorder programme\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/34.142.66.208\/#website\",\"url\":\"https:\/\/34.142.66.208\/\",\"name\":\"Psychedelic Health\",\"description\":\"News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/34.142.66.208\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/34.142.66.208\/#\/schema\/person\/188c12739a5906cf0b69fbf53f517f12\",\"name\":\"Stephanie Price\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/34.142.66.208\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/psychedelichealth.co.uk\/wp-content\/uploads\/2023\/05\/avatar_user_20_1684313043-96x96.jpg\",\"contentUrl\":\"https:\/\/psychedelichealth.co.uk\/wp-content\/uploads\/2023\/05\/avatar_user_20_1684313043-96x96.jpg\",\"caption\":\"Stephanie Price\"},\"description\":\"Stephanie is the editor of Psychedelic Health. Contact: stephanie@psych.global. Stephanie is a journalist writing about science, research, policy and industry developments in cannabis, CBD and psychedelics. In 2013 Stephanie gained her BA in English and Media, focusing on journalism and propaganda, and in 2015, received her National Council for the Training of Journalists (NCTJ) diploma whilst working as a reporter in North Wales. Stephanie has a specialism in Medical Cannabis: The Health Effects of THC and CBD through the University of Colorado, Boulder, and a certificate from the Medical Cannabis Clinicians Society on \\\"Medical Cannabis Explained\\\".\",\"sameAs\":[\"https:\/\/psychedelichealth.co.uk\",\"https:\/\/twitter.com\/https:\/\/twitter.com\/steph_jprice\"],\"url\":\"https:\/\/psychedelichealth.co.uk\/author\/stephanieprice\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"IND application submitted for psilocybin alcohol use disorder programme","description":"B.More has submitted an Investigational New Drug (IND) application for its Psilocybin Alcohol Use Disorder Programme.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/34.142.66.208\/2022\/07\/25\/psilocybin-alcohol-use-disorder-programme\/","og_locale":"en_GB","og_type":"article","og_title":"IND application submitted for psilocybin alcohol use disorder programme","og_description":"B.More has submitted an Investigational New Drug (IND) application for its Psilocybin Alcohol Use Disorder Programme.","og_url":"https:\/\/34.142.66.208\/2022\/07\/25\/psilocybin-alcohol-use-disorder-programme\/","og_site_name":"Psychedelic Health","article_publisher":"https:\/\/www.facebook.com\/Cannabis-Health-Magazine-1047415772315886\/?ref=bookmarks","article_published_time":"2022-07-25T14:48:27+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/34.142.66.208\/wp-content\/uploads\/2022\/07\/AdobeStock_223197658.jpeg","type":"image\/jpeg"}],"author":"Stephanie Price","twitter_card":"summary_large_image","twitter_creator":"@https:\/\/twitter.com\/steph_jprice","twitter_misc":{"Written by":"Stephanie Price","Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/34.142.66.208\/2022\/07\/25\/psilocybin-alcohol-use-disorder-programme\/","url":"https:\/\/34.142.66.208\/2022\/07\/25\/psilocybin-alcohol-use-disorder-programme\/","name":"IND application submitted for psilocybin alcohol use disorder programme","isPartOf":{"@id":"https:\/\/34.142.66.208\/#website"},"primaryImageOfPage":{"@id":"https:\/\/34.142.66.208\/2022\/07\/25\/psilocybin-alcohol-use-disorder-programme\/#primaryimage"},"image":{"@id":"https:\/\/34.142.66.208\/2022\/07\/25\/psilocybin-alcohol-use-disorder-programme\/#primaryimage"},"thumbnailUrl":"https:\/\/psychedelichealth.co.uk\/wp-content\/uploads\/2022\/07\/AdobeStock_223197658.jpeg","datePublished":"2022-07-25T14:48:27+00:00","dateModified":"2022-07-25T14:48:27+00:00","author":{"@id":"https:\/\/34.142.66.208\/#\/schema\/person\/188c12739a5906cf0b69fbf53f517f12"},"description":"B.More has submitted an Investigational New Drug (IND) application for its Psilocybin Alcohol Use Disorder Programme.","breadcrumb":{"@id":"https:\/\/34.142.66.208\/2022\/07\/25\/psilocybin-alcohol-use-disorder-programme\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/34.142.66.208\/2022\/07\/25\/psilocybin-alcohol-use-disorder-programme\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/34.142.66.208\/2022\/07\/25\/psilocybin-alcohol-use-disorder-programme\/#primaryimage","url":"https:\/\/psychedelichealth.co.uk\/wp-content\/uploads\/2022\/07\/AdobeStock_223197658.jpeg","contentUrl":"https:\/\/psychedelichealth.co.uk\/wp-content\/uploads\/2022\/07\/AdobeStock_223197658.jpeg","width":1200,"height":800,"caption":"UK-funded trial to investigate ketamine for alcohol addiction"},{"@type":"BreadcrumbList","@id":"https:\/\/34.142.66.208\/2022\/07\/25\/psilocybin-alcohol-use-disorder-programme\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/34.142.66.208\/"},{"@type":"ListItem","position":2,"name":"IND application submitted for psilocybin alcohol use disorder programme"}]},{"@type":"WebSite","@id":"https:\/\/34.142.66.208\/#website","url":"https:\/\/34.142.66.208\/","name":"Psychedelic Health","description":"News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/34.142.66.208\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/34.142.66.208\/#\/schema\/person\/188c12739a5906cf0b69fbf53f517f12","name":"Stephanie Price","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/34.142.66.208\/#\/schema\/person\/image\/","url":"https:\/\/psychedelichealth.co.uk\/wp-content\/uploads\/2023\/05\/avatar_user_20_1684313043-96x96.jpg","contentUrl":"https:\/\/psychedelichealth.co.uk\/wp-content\/uploads\/2023\/05\/avatar_user_20_1684313043-96x96.jpg","caption":"Stephanie Price"},"description":"Stephanie is the editor of Psychedelic Health. Contact: stephanie@psych.global. Stephanie is a journalist writing about science, research, policy and industry developments in cannabis, CBD and psychedelics. In 2013 Stephanie gained her BA in English and Media, focusing on journalism and propaganda, and in 2015, received her National Council for the Training of Journalists (NCTJ) diploma whilst working as a reporter in North Wales. Stephanie has a specialism in Medical Cannabis: The Health Effects of THC and CBD through the University of Colorado, Boulder, and a certificate from the Medical Cannabis Clinicians Society on \"Medical Cannabis Explained\".","sameAs":["https:\/\/psychedelichealth.co.uk","https:\/\/twitter.com\/https:\/\/twitter.com\/steph_jprice"],"url":"https:\/\/psychedelichealth.co.uk\/author\/stephanieprice\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/psychedelichealth.co.uk\/wp-json\/wp\/v2\/posts\/17621"}],"collection":[{"href":"https:\/\/psychedelichealth.co.uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/psychedelichealth.co.uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/psychedelichealth.co.uk\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/psychedelichealth.co.uk\/wp-json\/wp\/v2\/comments?post=17621"}],"version-history":[{"count":0,"href":"https:\/\/psychedelichealth.co.uk\/wp-json\/wp\/v2\/posts\/17621\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/psychedelichealth.co.uk\/wp-json\/wp\/v2\/media\/17622"}],"wp:attachment":[{"href":"https:\/\/psychedelichealth.co.uk\/wp-json\/wp\/v2\/media?parent=17621"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/psychedelichealth.co.uk\/wp-json\/wp\/v2\/categories?post=17621"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/psychedelichealth.co.uk\/wp-json\/wp\/v2\/tags?post=17621"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}